MoonLake Immunotherapeutics (MEX:MLTXN) ROCE %: -72.96% (As of Mar. 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics ROCE %?

MoonLake Immunotherapeutics MEX:MLTXN 30 ROCE % is -72.96% as of Mar. 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MoonLake Immunotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -72.96%.

MoonLake Immunotherapeutics  (MEX:MLTXN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MoonLake Immunotherapeutics ROCE % Related Terms

MoonLake Immunotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics ROCE % Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 -227.58 -14.76 -27.62 -49.08

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.95 -44.83 -66.54 -64.67 -72.96
MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics ROCE % Calculation

MoonLake Immunotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4005.584/( ( (9967.627 - 468.482) + (7642.213 - 818.863) )/ 2 )
=-4005.584/( (9499.145+6823.35)/ 2 )
=-4005.584/8161.2475
=-49.08 %

MoonLake Immunotherapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-4819.492/( ( (7642.213 - 818.863) + (7219.824 - 831.56) )/ 2 )
=-4819.492/( ( 6823.35 + 6388.264 )/ 2 )
=-4819.492/6605.807
=-72.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -72.96% mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a ROCE % of -72.96% as of Mar. 2026.
Is MoonLake Immunotherapeutics' ROCE % too high?
MoonLake Immunotherapeutics' current ROCE % is -72.96%. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' ROCE % compare to AVBP and BCAX?
MoonLake Immunotherapeutics' ROCE % of -72.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. MoonLake Immunotherapeutics's current ROCE % is -72.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current ROCE % of -72.96%. The current ROCE % is -72.96%. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current ROCE % is -72.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price